WuXi AppTec cites integrated CRDMO model as way to speed IND readiness

WuXi AppTec says its integrated CRDMO model can help biotechnology partners move from discovery to IND faster by linking biology, DMPK, toxicology, bioanalysis and CMC under one development plan. The company points to case studies in rare disease, molecular-glue degraders, siRNA-lipid conjugates and expedited manufacturing as evidence of shorter timelines and fewer technical handoffs.

Why it matters: - Biotechnology companies face pressure to coordinate biology, safety, bioanalysis and manufacturing before an IND submission. - Fragmented vendor networks can slow development, weaken knowledge continuity and add program risk. - WuXi AppTec is positioning its integrated CRDMO model as a way to reduce those bottlenecks, especially for complex modalities such as targeted protein degraders, oligonucleotides, peptides and conjugated medicines.

What happened: - WuXi AppTec described how its CRDMO model connects discovery, development and manufacturing from early research through IND submission. - The company highlighted case studies showing how integrated teams handled DMPK, toxicology, bioanalysis, CMC and manufacturing challenges across different programs. - The examples covered a rare-disease therapy, a molecular glue degrader, a siRNA-lipid conjugate and an expedited API and drug product campaign for a U.S. biotechnology company.

The details: - IND preparation requires coordinated decisions across biology, DMPK, toxicology, bioanalysis and CMC because each dataset affects candidate selection, safety assessment, dose planning and regulatory readiness. - WuXi Biology supports early discovery with target discovery, assay design, hit identification, in vivo model selection and translational strategy. - WuXi AppTec said its biology platform incorporates quality considerations early and supports programs through the preclinical stage. - In one rare-disease program, WuXi AppTec brought together DMPK, formulation development and toxicology teams when conventional toxicology approaches were not sufficient. - The teams built a cross-functional validation strategy in fewer than three months and completed GLP-compliant toxicology studies on schedule, allowing the client to file an IND as planned. - For a molecular glue degrader program, standard target occupancy assays could not reliably measure intracellular target degradation. - WuXi AppTec’s Bioanalytical Services team developed a customized intracellular pharmacodynamic assay through reagent screening, assay optimization and workflow standardization. - The method generated reliable target degradation data and supported continued IND development. - The pharmacodynamic findings were evaluated alongside DMPK, CMC and broader development strategy within the CRDMO framework. - In a siRNA-lipid conjugate program, the original solid-phase synthesis route depended on customized lipid-functionalized support and faced long procurement times, poor coupling efficiency and difficult impurity removal. - WuXi TIDES redesigned the process so oligonucleotide synthesis came first, followed by solution-phase lipid conjugation. - The new route improved supply control, achieved up to 95% homogeneous conversion, increased crude purity by about 20%, consolidated two purification steps into one and kept endotoxin below 0.05 EU/mg in the final API. - Lipid synthesis, process development, analytical validation, formulation and manufacturing moved forward under one program plan. - The candidate reached CMC readiness for IND submission in fewer than nine months. - For a U.S. biotechnology company preparing for Phase I development, WuXi AppTec coordinated API and drug product manufacturing in the same building. - API manufacturing finished in about ten weeks while analytical methods were developed in parallel. - Drug product manufacturing followed after API release and delivered clinical materials in two dosage strengths within six weeks. - After stability testing, the program reached IND readiness within five months.

Between the lines: - The cases show that the biggest value of an integrated model is not just speed. - The larger gain is continuity across scientific decisions, which can reduce rework when a program moves from discovery to regulatory submission. - The examples also suggest that complex modalities benefit most when analytical, manufacturing and safety functions are planned together instead of handed off in sequence.

What's next: - WuXi AppTec is likely to keep using these examples to support its pitch to biotechnology companies developing first-in-class and complex therapies. - For sponsors, the practical question will be whether integrated execution can consistently shorten timelines while preserving data quality and regulatory confidence. - As more programs move into complex modalities, demand may grow for development models that combine testing, chemistry and manufacturing under one operating plan.

The bottom line: - WuXi AppTec is arguing that integrated CRDMO execution can help biotech partners reach IND readiness faster, with fewer handoffs and better control over technical risk.